Imipenem/cilastatin: the first carbapenem antibiotic

Area of Science:

• Pharmacology
• Infectious Diseases
• Microbiology

Background:

• Imipenem/cilastatin represents the first carbapenem antibiotic, a new class of beta-lactams.
• Its antibacterial spectrum is exceptionally broad, encompassing gram-positive, gram-negative, and anaerobic organisms.

Purpose of the Study:

• To evaluate the efficacy and safety of imipenem/cilastatin.
• To compare imipenem/cilastatin with existing combination antibiotic therapies.

Main Methods:

• Phase II and III clinical trials were conducted.
• Comparative clinical trials assessed efficacy against combination therapy.

Main Results:

• Imipenem/cilastatin demonstrated effectiveness in treating soft tissue infections, endocarditis, obstetrics and gynecology infections, complicated urinary tract infections, mixed anaerobic-aerobic infections, osteomyelitis, bacteremias, and pneumonias.
• Efficacy was comparable to combination antibiotic therapy in clinical trials.
• Common adverse events included phlebitis, diarrhea, nausea, rash, and elevated hepatic enzymes, similar to other beta-lactam antibiotics.

Conclusions:

• Imipenem/cilastatin exhibits a broad spectrum of activity and is effective in treating a wide range of infections.
• It serves as a viable alternative to combination antibiotic therapy.
• Cilastatin co-administration enhances urinary recovery of imipenem by inhibiting renal dehydropeptidase.